EDITORIAL SECTION

Articles

How to Optimize Batch Production in European Pharmaceutical Manufacturing?

Efficient and highquality batch production is crucial for success in the European pharmaceutical industry This short introduction explores key strategies for optimizing manufacturing processes

The Unprecedented Surge of Biopharmaceuticals in the European Market

Recent years have seen a significant upheaval in the European pharmaceutical scene marked by an unparalleled surge in biopharmaceutical prominence This shift isnt fleeting but signifies a profound and enduring transformation To fully grasp this paradigm shift its essential to explore the complex interplay of scientific advancements market dynamics regulatory frameworks economic factors and global...

From Digital Transformation to Intelligent Pharma: How AI Is Reshaping Pharmaceutical Strategy

Pharmas digital transformation has solved one problem well access to information Market signals arrive continuously Commercial teams generate customer and channel data medical and scientific functions accumulate new evidence and supply and finance teams produce operational signals that enterprise platforms can now connect across what were once separate systems

mRNA and Oligonucleotide Therapeutics: Emerging Synergies in Genetic Medicine

MRNA therapies work by introducing synthetic mRNA encoding a therapeutic protein enabling transient protein expression that can replace deficient enzymes stimulate immune responses or facilitate gene editing This additive approach is beneficial for diseases caused by lossoffunction mutations or when temporary protein expression is desired

The 2025 Agenda: Navigating New European Compliance Challenges in Pharma

EU pharma industry expectate new regulations changes in the year European Medicines Agency EMA and other regulatory authorities in the continent gradually increase regulatory requirements that exercise greater pressure on business entities to implement patientoriented sustainable and innovative production standards

Real-World Evidence in Pharmaceutical Drug Development

For most of the past halfcentury the randomised controlled trial has been the undisputed gatekeeper of pharmaceutical value It remains the gold standard for establishing causality and nothing in this article suggests otherwise Yet the controlled trial answers a narrow question under artificial conditions does a drug work in a carefully selected population managed by expert investigators over a fix...

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys